PL1824481T3 - Zastosowanie rybozo-cysteiny do leczenia niedotlenienia przez zwiększenie dostarczania glutationu i poziomów ATP w komórkach - Google Patents
Zastosowanie rybozo-cysteiny do leczenia niedotlenienia przez zwiększenie dostarczania glutationu i poziomów ATP w komórkachInfo
- Publication number
- PL1824481T3 PL1824481T3 PL05823154T PL05823154T PL1824481T3 PL 1824481 T3 PL1824481 T3 PL 1824481T3 PL 05823154 T PL05823154 T PL 05823154T PL 05823154 T PL05823154 T PL 05823154T PL 1824481 T3 PL1824481 T3 PL 1824481T3
- Authority
- PL
- Poland
- Prior art keywords
- ribose
- glutathione
- cysteine
- cells
- atp levels
- Prior art date
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title 2
- 108010024636 Glutathione Proteins 0.000 title 1
- 206010021143 Hypoxia Diseases 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 229960003180 glutathione Drugs 0.000 title 1
- 230000007954 hypoxia Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/990,933 US20060105972A1 (en) | 2004-11-17 | 2004-11-17 | Method to enhance delivery of glutathione and ATP levels in cells |
PCT/US2005/041458 WO2006055597A1 (en) | 2004-11-17 | 2005-11-16 | Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells |
EP05823154A EP1824481B1 (en) | 2004-11-17 | 2005-11-16 | Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1824481T3 true PL1824481T3 (pl) | 2012-11-30 |
Family
ID=35759146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05823154T PL1824481T3 (pl) | 2004-11-17 | 2005-11-16 | Zastosowanie rybozo-cysteiny do leczenia niedotlenienia przez zwiększenie dostarczania glutationu i poziomów ATP w komórkach |
Country Status (14)
Country | Link |
---|---|
US (4) | US20060105972A1 (pl) |
EP (1) | EP1824481B1 (pl) |
JP (1) | JP2008520681A (pl) |
KR (1) | KR20070095900A (pl) |
CN (1) | CN101060840A (pl) |
AU (1) | AU2005307885B2 (pl) |
BR (1) | BRPI0516814A (pl) |
CA (1) | CA2587616C (pl) |
DK (1) | DK1824481T3 (pl) |
EA (1) | EA014076B1 (pl) |
ES (1) | ES2390228T3 (pl) |
MX (1) | MX2007005835A (pl) |
PL (1) | PL1824481T3 (pl) |
WO (1) | WO2006055597A1 (pl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105972A1 (en) | 2004-11-17 | 2006-05-18 | Nagasawa Herbert T | Method to enhance delivery of glutathione and ATP levels in cells |
JP4982755B2 (ja) * | 2006-06-27 | 2012-07-25 | 国立大学法人 長崎大学 | 高速液体クロマトグラフィーによる糖及び類縁アルデヒド化合物の絶対配置決定法 |
US8685951B2 (en) | 2007-03-27 | 2014-04-01 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods for cytoprotection |
CN102387805A (zh) * | 2008-04-02 | 2012-03-21 | 生物能公司 | 核糖在对于急性心肌梗塞的第一反应中的用途 |
TW201201712A (en) * | 2010-01-28 | 2012-01-16 | Max International Llc | Compositions comprising sugar-cysteine products |
TW201202209A (en) * | 2010-01-28 | 2012-01-16 | Max International Llc | Methods of preparing thiazolidines |
US20110287109A1 (en) * | 2010-05-24 | 2011-11-24 | Max International, Llc | Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products |
WO2013016636A1 (en) * | 2011-07-27 | 2013-01-31 | Max International, Llc | Compositions comprising sugar-cysteine products |
CA2986889C (en) * | 2015-05-22 | 2023-08-29 | The A2 Milk Company Limited | Beta-casein a2 and antioxidant capacity |
US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1120033B (it) | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
US4335210A (en) * | 1981-02-11 | 1982-06-15 | Cornell Research Foundation | Method of producing L-cysteine |
US4647571A (en) | 1981-02-11 | 1987-03-03 | Cornell Research Foundation | Cysteine delivery composition |
US4719201A (en) * | 1985-02-07 | 1988-01-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia |
US4605644A (en) * | 1985-02-07 | 1986-08-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia employing ribose and adenine |
US4736060A (en) | 1985-08-06 | 1988-04-05 | Nippon Rikagakuyakuhin Co., Ltd. | Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine |
JPS63152325A (ja) | 1986-08-20 | 1988-06-24 | Yamanouchi Pharmaceut Co Ltd | 脳虚血症予防治療剤 |
US4868114A (en) * | 1987-08-05 | 1989-09-19 | Regents Of The University Of Minnesota | Method for elevating glutathione levels |
US5095027A (en) * | 1991-02-28 | 1992-03-10 | Clintec Nutrition Co. | Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid |
US5631234A (en) * | 1991-04-15 | 1997-05-20 | Teijin Limited | Method for treating ischemia-reperfusion tissue injury |
TW259709B (pl) * | 1991-04-15 | 1995-10-11 | Teijin Ltd | |
US5292538A (en) | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
JPH10139665A (ja) * | 1996-09-12 | 1998-05-26 | Sankyo Co Ltd | トログリタゾンを含有するグルタチオン還元酵素活性増強剤 |
AU6141498A (en) | 1997-02-04 | 1998-08-25 | John V. Kosbab | Compositions and methods for prevention and treatment of vascular degenerative diseases |
US6730336B2 (en) | 1998-01-30 | 2004-05-04 | The Procter & Gamble Co. | Fortified beverages with improved texture and flavor impact at lower dosage of solids |
US6218366B1 (en) * | 1998-06-19 | 2001-04-17 | Bioenergy, Inc. | Method for raising the hypoxic threshold |
US7153503B1 (en) | 1998-12-19 | 2006-12-26 | Janeel Henderson | Comprehensive dietary supplement |
US6534480B2 (en) * | 1999-06-17 | 2003-03-18 | Bioenergy Inc. | Compositions for increasing energy in vivo |
US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
US6881425B2 (en) | 2001-08-31 | 2005-04-19 | Council Of Scientific And Industrial Research | Custom made herbal health promotive formulation for females/expectant mothers |
US6572899B1 (en) | 2002-07-03 | 2003-06-03 | Vitacost.Com, Inc. | Memory loss treatment formulation |
US7455857B2 (en) | 2003-04-08 | 2008-11-25 | Janeel Henderson | Energy generating composition |
GB0319463D0 (en) | 2003-08-20 | 2003-09-17 | Givaudan Sa | Compounds |
US20050100537A1 (en) | 2003-11-10 | 2005-05-12 | Evans Gregory S. | Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
US20060105972A1 (en) | 2004-11-17 | 2006-05-18 | Nagasawa Herbert T | Method to enhance delivery of glutathione and ATP levels in cells |
US8962058B2 (en) | 2005-11-23 | 2015-02-24 | The Coca-Cola Company | High-potency sweetener composition with antioxidant and compositions sweetened therewith |
MY166532A (en) | 2006-02-10 | 2018-07-10 | Mannatech Inc | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
US8685951B2 (en) | 2007-03-27 | 2014-04-01 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods for cytoprotection |
WO2010033915A2 (en) | 2008-09-19 | 2010-03-25 | Unicity International Inc. | Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix |
TW201201712A (en) | 2010-01-28 | 2012-01-16 | Max International Llc | Compositions comprising sugar-cysteine products |
US20110287109A1 (en) | 2010-05-24 | 2011-11-24 | Max International, Llc | Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products |
-
2004
- 2004-11-17 US US10/990,933 patent/US20060105972A1/en not_active Abandoned
-
2005
- 2005-11-16 EP EP05823154A patent/EP1824481B1/en active Active
- 2005-11-16 JP JP2007543186A patent/JP2008520681A/ja active Pending
- 2005-11-16 MX MX2007005835A patent/MX2007005835A/es unknown
- 2005-11-16 CA CA2587616A patent/CA2587616C/en active Active
- 2005-11-16 EA EA200701017A patent/EA014076B1/ru not_active IP Right Cessation
- 2005-11-16 PL PL05823154T patent/PL1824481T3/pl unknown
- 2005-11-16 CN CNA2005800393226A patent/CN101060840A/zh active Pending
- 2005-11-16 DK DK05823154.9T patent/DK1824481T3/da active
- 2005-11-16 WO PCT/US2005/041458 patent/WO2006055597A1/en active Application Filing
- 2005-11-16 KR KR1020077013535A patent/KR20070095900A/ko not_active Application Discontinuation
- 2005-11-16 AU AU2005307885A patent/AU2005307885B2/en not_active Ceased
- 2005-11-16 ES ES05823154T patent/ES2390228T3/es active Active
- 2005-11-16 BR BRPI0516814-7A patent/BRPI0516814A/pt not_active IP Right Cessation
-
2008
- 2008-07-30 US US12/182,354 patent/US8501700B2/en active Active
-
2013
- 2013-08-02 US US13/958,530 patent/US9144570B2/en active Active
-
2015
- 2015-08-27 US US14/838,274 patent/US20160082029A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101060840A (zh) | 2007-10-24 |
EA200701017A1 (ru) | 2007-10-26 |
CA2587616A1 (en) | 2006-05-26 |
EP1824481A1 (en) | 2007-08-29 |
KR20070095900A (ko) | 2007-10-01 |
CA2587616C (en) | 2015-03-17 |
US20160082029A1 (en) | 2016-03-24 |
AU2005307885A1 (en) | 2006-05-26 |
AU2005307885A2 (en) | 2006-05-26 |
EP1824481B1 (en) | 2012-08-29 |
US20090042822A1 (en) | 2009-02-12 |
EA014076B1 (ru) | 2010-08-30 |
US20060105972A1 (en) | 2006-05-18 |
BRPI0516814A (pt) | 2008-09-23 |
JP2008520681A (ja) | 2008-06-19 |
MX2007005835A (es) | 2007-10-08 |
US9144570B2 (en) | 2015-09-29 |
WO2006055597A1 (en) | 2006-05-26 |
ES2390228T3 (es) | 2012-11-07 |
DK1824481T3 (da) | 2012-09-24 |
AU2005307885B2 (en) | 2010-12-23 |
US20130317072A1 (en) | 2013-11-28 |
US8501700B2 (en) | 2013-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1824481T3 (pl) | Zastosowanie rybozo-cysteiny do leczenia niedotlenienia przez zwiększenie dostarczania glutationu i poziomów ATP w komórkach | |
EP1766768A4 (en) | USE OF LACRITINE AS A PROMOTER OF EYE CELL OVER LIFE | |
EP1758450A4 (en) | IMPROVEMENTS AT BZW. REGARDLESS PLANT TREATMENT AGENTS | |
GB0514891D0 (en) | Improvements in and relating to implants | |
EP1993592A4 (en) | COMPOSITIONS WITH LACTOFERRIN AND METHOD FOR USE THAT TO AIM IN THE GROWTH OF SKIN CELLS | |
WO2009050267A3 (en) | Il24 for inducing hyperproliferative or autoimmune cell death | |
GB0422566D0 (en) | Improvements in or relating to closure retention and relaese mechanisms | |
GB2431973B (en) | Improvements in and relating to construction | |
GB0406835D0 (en) | Improvements in and relating to implants | |
GB2417688B (en) | Improvements in and relating to neurostimulation | |
GB0523474D0 (en) | Improvements in and relating to electrodes | |
GB2432823B (en) | Improvements in and relating to containers | |
GB0516962D0 (en) | Improvements in and relating to investigations | |
GB0516392D0 (en) | Improvements in and relating to wool treatment | |
GB2438023B (en) | Improvements In And Relating To Construction | |
GB0718156D0 (en) | Improvements in and relating to investigations | |
GB0502142D0 (en) | Improvements in and relating to water wheels | |
GB0620082D0 (en) | Improvements in and relating to calculation of resting metabolic rate | |
GB0511530D0 (en) | Improvements in and relating to fencing | |
GB0417619D0 (en) | Improvements in and relating to fencing | |
GB0403550D0 (en) | Improvements in and relating to erectile dysfunction | |
GB0425796D0 (en) | Improvements in and relating to electrodes | |
GB2454995B (en) | Improvements in and relating to packaging | |
GB0410746D0 (en) | Improvements in and relating to pelmets | |
GB0406832D0 (en) | Improvements in and relating to implants |